There's an excellent article in this morning's New York Times on the quest by the Cochrane group to determine the efficacy of Tamiflu, which is part of a bigger story on how pharmaceutical companies selectively release data regarding their products. It demonstrates how epidemiology can involve more than just data analysis and how political activism is sometimes required to find the data to answer basic questions.
Photo: Dr. Tom Jefferson by Chris Warde-Jones for the New York Times.
Pondering vexing issues in infection prevention and control
Subscribe to:
Post Comments (Atom)
OSHA! OSHA! OSHA!
In many parts of the country, as rates of COVID-19 are declining and vaccination coverage is increasing (albeit with substantial variati...
-
Back on clinical service again and having more thoughts on poor hospital design. Last month I wondered why there were no stethoscope wipe...
-
Those that follow me on twitter or the blog have probably noticed my recent focus on trying to understand the emergence of compulsory influe...
-
REUTERS/Athit Perawongmetha With the assistance of a great supply management team, we have been able to outfit all of our clinical staff wit...

No comments:
Post a Comment
Thanks for submitting your comment to the Controversies blog. To reduce spam, all comments will be reviewed by the blog moderator prior to publishing. However, all legitimate comments will be published, whether they agree with or oppose the content of the post.